Severe Acute Respiratory Syndrome Coronavirus 2 Third Vaccine Immune Response in Multiple Sclerosis Patients Treated with Ocrelizumab

Livnat Brill, Catarina Raposo, Ariel Rechtman, Omri Zveik, Netta Levin, Esther Oiknine-Djian, Dana G. Wolf, Adi Vaknin-Dembinsky*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Abstract

The introduction of a third-dose vaccination along with new variants of concern raises questions regarding serology and T-cell responses in patients with multiple sclerosis (pwMS) treated with B-cell depletion who develop attenuated humoral response to vaccines. The aim of this study was to longitudinally evaluate humoral and cellular response to SARS-CoV-2 mRNA vaccine in ocrelizumab-treated pwMS before and following a third vaccine dose. Following the third vaccine dose, patients who are low or nonresponders following initial vaccination did not increase antibody titers. In healthy controls and ocrelizumab-treated pwMS, cellular response decreased 6 months after initial vaccination and increased significantly after the third dose. ANN NEUROL 2022;91:796–800.

Original languageAmerican English
Pages (from-to)796-800
Number of pages5
JournalAnnals of Neurology
Volume91
Issue number6
DOIs
StatePublished - Jun 2022
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2022 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.

Fingerprint

Dive into the research topics of 'Severe Acute Respiratory Syndrome Coronavirus 2 Third Vaccine Immune Response in Multiple Sclerosis Patients Treated with Ocrelizumab'. Together they form a unique fingerprint.

Cite this